This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AUSTRALIAN PRODUCT INFORMATION Rozlytrek™ (entrectinib)

1. NAME OF THE MEDICINE

entrectinib

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 100 mg hard capsule contains 100 mg entrectinib.

Each 200 mg hard capsule contains 200 mg entrectinib.

Entrectinib has the molecular formula $C_{31}H_{34}F_2N_6O_2$. The molecular weight is 560.6. The chemical name is N-{5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl}-4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide. The solubility in aqueous media decreases over the range pH 1.2 to pH 8.0.

Excipients with known effect

Each 100 mg hard capsule contains 65 mg lactose. Each 200 mg hard capsule contains 130 mg lactose. For the full list of excipients, see section 6.1 *List of excipients*.

3. PHARMACEUTICAL FORM

Hard capsule.

Rozlytrek 100 mg are size 2 hard capsules with yellow body and cap with "ENT 100" imprinted in blue on the body.

Rozlytrek 200 mg are size 0 hard capsules with orange body and cap with "ENT 200" imprinted in blue on the body.

4. CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Non-small cell lung cancer (NSCLC)

Rozlytrek is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours are ROS1-positive.

Solid tumours

Rozlytrek is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that:

- have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have either progressed following treatment or have no satisfactory alternative therapy.

This indication was approved via the **provisional approval** pathway, based on objective response rate and duration of response in single-arm trials. Full registration for this indication depends on verification and description of clinical benefit in confirmatory trials.

4.2 DOSE AND METHOD OF ADMINISTRATION

General

Method of administration

Rozlytrek can be taken with or without food. Capsules should be swallowed whole. Capsules must not be opened or dissolved.

Patient selection

Solid tumours

A validated assay is required for the selection of patients with NTRK fusion-positive locally advanced or metastatic solid tumours. NTRK fusion-positive status should be established prior to initiation of Rozlytrek therapy.

NSCLC

A validated assay is required for the selection of patients with ROS1-positive locally advanced or metastatic NSCLC. ROS1-positive status should be established prior to initiation of Rozlytrek therapy.

Dosage

Adults

The recommended dose of Rozlytrek for adults is 600 mg given orally, once daily (see section 5.2 *Pharmacokinetic properties*).

Paediatric patients

The recommended dose of Rozlytrek for paediatric patients is based on body surface area (BSA) as shown in Table 1 (see section 5.2 *Pharmacokinetic properties*).

Body surface area (BSA)	Recommended dosage (orally once daily)
Greater than 1.50 m ²	600 mg
1.11 to 1.50 m ²	500 mg
0.91 to 1.10 m ²	400 mg

 Table 1. Dosing in paediatric patients 12 years and older (adolescents)

Duration of treatment

It is recommended that patients are treated with Rozlytrek until disease progression or unacceptable toxicity.

Delayed or missed doses

If a planned dose of Rozlytrek is missed, patients can make up that dose unless the next dose is due within 12 hours. If vomiting occurs immediately after taking a dose of Rozlytrek, patients may repeat that dose.

Dose modifications for adverse reactions

Management of adverse reactions may require temporary interruption, dose reduction, or discontinuation of treatment with Rozlytrek.

Recommended dose reductions are provided in Table 2. The dose of Rozlytrek may be reduced up to 2 times, after which Rozlytrek treatment should be permanently discontinued if patients are unable to tolerate the lowest reduced dose.

Dose level	All adults, and paediatric patients with BSA greater than 1.50 m ² (orally once daily)	Paediatric patients with BSA of 1.11 to 1.50 m ² (orally once daily)	Paediatric patients with BSA of 0.91 to 1.10 m ² (orally once daily)		
(Starting dose)	(600 mg)	(500 mg)	(400 mg)		
Dose after first reduction	400 mg 400 mg 300 mg				
Dose after second reduction	200 mg 200 mg 200 mg				
Subsequently	Permanently discontinue Rozlytrek in patients who are unable to tolerate Rozlytrek after two dose reductions.				

Table 2. Recommended doses when reduction is required

Recommended dose modifications for specific adverse reactions are provided in Table 3. See sections 4.4 Special warnings and precautions for use and 4.8 Adverse effects (undesirable effects).

Adverse drug reaction	Severity*	Dose modification
Congestive heart failure	Grade 2 or 3	 Withhold Rozlytrek until recovered to less than or equal to Grade 1. Resume at reduced dose.
	Grade 4	• Permanently discontinue Rozlytrek.
Central nervous system effects	Intolerable Grade 2	 Withhold Rozlytrek until recovery to less than or equal to Grade 1 or to baseline. Resume at same dose or reduced dose, as clinically appropriate.
	Grade 3	 Withhold Rozlytrek until recovery to less than or equal to Grade 1 or to baseline. Resume at reduced dose.
	Grade 4	• Permanently discontinue Rozlytrek.
Hepatotoxicity	Grade 3	 Withhold Rozlytrek until recovery to less than or equal to Grade 1 or to baseline. Resume at same dose if resolution occurs within 4 weeks.

Table 3. Recommended dose modifications for specific adverse drug reactions

Adverse drug reaction	Severity *	Dose modification
		 Permanently discontinue if adverse reaction does not resolve within 4 weeks. Resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
	Grade 4	 Withhold Rozlytrek until recovery to less than or equal to Grade 1 or to baseline. Resume at reduced dose if resolution
		 occurs within 4 weeks. Permanently discontinue if adverse reaction does not resolve within 4 weeks. Permanently discontinue for recurrent
		Grade 4 events.
	ALT or AST greater than 3 times the upper limit of normal (ULN) with concurrent total bilirubin greater than 1.5 times ULN (in the absence of cholestasis or haemolysis).	• Permanently discontinue Rozlytrek.
Hyperuricaemia	Symptomatic or Grade 4	 Initiate urate-lowering medication. Withold Rozlytrek until improvement of signs or symptoms. Resume Rozlytrek at same or reduced dose.
QT interval prolongation	QTc 481 to 500 ms	 Withhold Rozlytrek until recovered to baseline Resume treatment at same dose
	QTc greater than 500 msec	 Withhold Rozlytrek until QTc interval recovers to baseline. Resume at same dose if factors that cause QT prolongation are identified and corrected. Resume at reduced dose if other factors that cause QT prolongation are not identified.
	Torsades de pointes, polymorphic ventricular tachycardia, or signs/symptoms of serious arrhythmia	• Permanently discontinue Rozlytrek.
Vision disorders	Grade 2 or above	 Withhold Rozlytrek until improvement or stabilisation. Resume at same dose or reduced dose, as clinically appropriate.
Anaemia or neutropenia	Grade 3 or Grade 4	• Withhold Rozlytrek until recovery to less than or equal to Grade 2.

Adverse drug reaction	Severity *	Dose modification
		• Resume treatment at the same dose or reduced dose, as clinically appropriate.
Other clinically relevant adverse reactions	Grade 3 or 4	 Withhold ROZLYTREK until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline. Resume at the same or reduced dose, if resolution occurs within 4 weeks. Permanently discontinue if adverse reaction does not resolve within 4 weeks. Permanently discontinue for recurrent Grade 4 events.

*Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Dose modifications for specific medicine interactions

Strong or moderate CYP3A inhibitors

Avoid concomitant use of strong or moderate CYP3A inhibitors with Rozlytrek (see section 4.5 Interactions with other medicines and other forms of interactions).

For adults and for paediatric patients 12 years and older who have a BSA greater than 1.50 m^2 , if the concomitant use of strong or moderate CYP3A inhibitors with Rozlytrek cannot be avoided, the Rozlytrek dose should be reduced to:

- 100 mg once daily if it is a strong CYP3A inhibitor and
- 200 mg once daily if it is a moderate CYP3A inhibitor.

After discontinuation of a strong or moderate CYP3A inhibitor, and after an appropriate washout period (3 to 5 times the elimination half-life of the CYP3A inhibitor), the Rozlytrek dose that was taken prior to initiating the CYP3A inhibitor can be resumed.

For paediatric patients 12 years and older who have a BSA less than or equal to 1.50 m^2 , the concomitant use of strong or moderate CYP3A inhibitors with Rozlytrek should be avoided altogether.

Avoid grapefruit products during treatment with Rozlytrek, as they contain inhibitors of CYP3A.

Strong or moderate CYP3A inducers

Avoid concomitant use of Rozlytrek with strong or moderate CYP3A inducers in adult and paediatric patients (See section 4.5 Interactions with other medicines and other forms of interactions).

Drugs that prolong the QT interval

Avoid co-administration of Rozlytrek with other products known to prolong the QT/QTc interval (see section 4.4 Special warnings and precautions for use and section 4.5 Interactions with other medicines and other forms of interactions).

Dosing in special populations

Paediatric populations

Dosage for patients is based on body surface area (mg/m^2) (see Table 1 for paediatric dosing).

Renal impairment

No dose adjustment is required in patients with mild or moderate renal impairment (CLcr 30 to < 90 mL/min calculated by Cockcroft-Gault equation). Rozlytrek has not been studied in patients with severe renal impairment (CLcr < 30 mL/min). However, since entrectinib elimination via the kidney is negligible, no dose adjustment is required in patients with severe renal impairment (see sections 4.4 *Special warnings and precautions for use* and 5.2 *Pharmacokinetic properties*).

Hepatic impairment

No dose adjustment is required in patients with underlying mild (Child-Pugh A), moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment, based on a study in subjects with hepatic impairment (see sections 4.4 *Special warnings and precautions for use* and 5.2 *Pharmacokinetic properties*). Patients with severe hepatic impairment should be carefully monitored for hepatic function and adverse reactions.

4.3 CONTRAINDICATIONS

Rozlytrek is contraindicated in patients with a known hypersensitivity to entrectinib or any of the excipients.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Congestive heart failure

Congestive heart failure (CHF) has been reported across clinical trials with Rozlytrek (see section 4.8 *Adverse effects (undesirable effects)*). These reactions were observed in patients with or without a history of cardiac disease and resolved upon treatment with diuretics and/or dose reduction/interruption of Rozlytrek. Assess left ventricular ejection fraction (LVEF) prior to initiation of Rozlytrek in patients with symptoms or known risk factors for CHF. Monitor patients for clinical signs and symptoms of CHF, including shortness of breath and oedema. For patients with myocarditis, with or without a decreased ejection fraction, MRI or cardiac biopsy may be required to make the diagnosis. For patients with new onset or worsening CHF, withhold Rozlytrek, institute appropriate medical management, and reassess LVEF. Based on the severity of CHF, modify Rozlytrek treatment as described in Table 3 (see section 4.2 *Dose and method of administration*).

Central nervous system effects

A broad spectrum of central nervous system (CNS) adverse reactions were reported in clinical trials with Rozlytrek, including cognitive impairment, mood disorders, dizziness and sleep disturbances (see section 4.8 *Adverse effects (undesirable effects)*). Monitor for signs of CNS adverse reactions, and advise patients and caregivers of these risks with Rozlytrek. Advise patients not to drive or operate hazardous machinery if they are experiencing CNS adverse

reactions (see section 4.7 *Effects on ability to drive and use machines*). Based on the severity of the CNS effects, modify Rozlytrek treatment as described in Table 3 (see section 4.2 *Dose and method of administration*).

Skeletal fractures

Rozlytrek increases the risk of fractures (see section 4.8 Adverse effects (undesirable effects) – Description of selected adverse events). Promptly evaluate patients with signs or symptoms (e.g., pain, changes in mobility, deformity) of fractures. In adult patients, some fractures occurred in the setting of a fall or other trauma to the affected area, while in paediatric patients fractures occurred in patients with minimal or no trauma. There are no data on the effects of Rozlytrek on healing of known fractures and risk of future fractures. In the majority of paediatric patients treatment was continued with Rozlytrek and the fracture healed.

Hepatotoxicity

Hepatic transaminase elevation was frequently reported in entrectinib clinical trials (see section 4.8 *Adverse effects (undesirable effects)*), and hepatotoxicity is a known effect of other ROS1 inhibitors. Monitor liver function tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Based on the severity of hepatic enzyme elevation, modify Rozlytrek treatment as described in Table 3 (see section 4.2 *Dose and method of administration*).

Hyperuricaemia

Hyperuricaemia was frequently reported in entrectinib clinical trials (see section 4.8 *Adverse effects* (*undesirable effects*)), and 34% of cases required medical intervention to reduce serum urate. Assess serum urate prior to initiating Rozlytrek and periodically during treatment. Monitor patients for signs and symptoms of hyperuricaemia. Initiate treatment with urate-lowering medications as clinically indicated and withhold Rozlytrek for signs and symptoms of hyperuricaemia, as described in Table 3 (see section 4.2 *Dose and method of administration*).

QTc interval prolongation

QT interval prolongation was observed in patients treated with Rozlytrek in clinical trials (see section 4.8 Adverse effects (undesirable effects)). Monitor patients who have QTc interval prolongation or are at significant risk of developing it, including patients with congenital long QT syndrome, clinically significant bradyarrhythmias, severe or poorly controlled heart failure and patients taking medications that are associated with QT interval prolongation. Assess QT interval and electrolytes at baseline and periodically during treatment, adjusting frequency based upon risk factors such as congestive heart failure, electrolyte abnormalities, or concomitant medications. Based on the severity of any QT interval prolongation observed, modify Rozlytrek treatment as described in Table 3 (see section 4.2 Dose and method of administration).

Vision disorders

Vision changes were reported in 21% of patients treated with Rozlytrek in clinical trials (see section 4.8 Adverse effects (undesirable effects)). For patients with new visual changes or changes that interfere with activities of daily living, modify Rozlytrek treatment as described in Table 3 (see section 4.2 Dose and method of administration).

Paediatric use

There is limited clinical experience with Rozlytrek in paediatric patients. Rozlytrek had effects on growth and development in juvenile rats (see section 5.3 *Preclinical safety data*).

The effectiveness of Rozlytrek in paediatric patients (12 years of age and older) was established based on extrapolation of data from three open-label, single-arm clinical trials in adult patients with solid tumours harboring an NTRK gene fusion (ALKA, STARTRK-1, and STARTRK-2) and pharmacokinetic data in paediatric patients enrolled in STARTRK-NG. Rozlytrek doses based on body surface area in paediatric patients 12 years and older resulted in similar systemic exposure compared to that in adults who received a Rozlytrek dose of 600 mg (see sections 4.2 *Dose and method of administration*, 5.1 *Pharmacodynamic properties – Clinical trials* and 5.2 *Pharmacokinetic properties – Pharmacokinetics in special populations*).

The safety of Rozlytrek in paediatric patients 12 years of age and older was established based on extrapolation of data in adults and data from 30 paediatric patients enrolled in STARTRK-NG. Of these 30 patients, 7% were <2 years (n=2), 77% were 2 to <12 years (n=23), 17% were 12 to <18 years (n=5); 57% had metastatic disease (n=17) and 44% had locally advanced disease (n=13); and all patients had received prior treatment for their cancer, including surgery, radiotherapy, or systemic therapy. The most common cancers were neuroblastoma (47%), primary CNS tumours (30%), and sarcoma (10%). The median duration of exposure for all paediatric patients was 4.2 months (range: 0.2 to 22.7 months).

Due to the small number of paediatric and adult patients, the single arm design of clinical studies of Rozlytrek, and confounding factors such as differences in susceptibility to infections between paediatric and adult patients, it is not possible to determine whether the observed differences in the incidence of adverse reactions to Rozlytrek are related to patient age or other factors. In an expanded safety database that included 338 adult patients and 30 paediatric patients who received Rozlytrek across clinical trials, the Grade 3 or 4 adverse reactions and laboratory abnormalities that occurred more frequently (\geq 5%) in paediatric patients (n=30) compared with adults (n=338) were neutropenia (27% vs 2%), bone fractures (23% vs 5%), increased weight (20% vs 7%), thrombocytopenia (10% vs 0.3%), lymphopenia (7% vs 0.3%). Three paediatric patients discontinued Rozlytrek due to an adverse reaction (Grade 4 pulmonary oedema, Grade 3 dyspnoea, and Grade 4 pancreatitis).

Rozlytrek was associated with a higher incidence of skeletal fractures in the paediatric patients compared to adult patients (see section 4.4 *Special warnings and precautions for use and* 4.8 *Adverse effects (undesirable effects) – Description of selected adverse events).*

The safety and effectiveness of Rozlytrek in paediatric patients less than 12 years of age with solid tumours who have an NTRK gene fusion have not been established.

The safety and effectiveness of Rozlytrek in paediatric patients with ROS1-positive NSCLC have not been established.

Use in hepatic impairment

The pharmacokinetics of entrectinib were studied in subjects with hepatic impairment due to cirrhosis and subjects with normal hepatic function. Following administration of a single oral dose of 100 mg entrectinib, the AUC_{inf} geometric mean ratio (90% CI) of entrectinib were 1.57 (1.03, 2.41) for the mild (Child-Pugh A), 1.54 (1.06, 2.24) for the moderate (Child-Pugh B), and 1.80 (1.22, 2.66) for the severe (Child-Pugh C) hepatic impaired groups compared to the normal hepatic function group. The combined AUC_{last} of entrectinib and M5 showed no relevant change in the hepatic impaired groups compared to the normal hepatic function group. The AUC_{last} geometric mean ratio (90% CI) were 1.30 (0.889, 1.89) for the mild, 1.24 (0.886, 1.89) for the mild, 1.80 for the mild for the mi

1.73) for the moderate, and 1.39 (0.988, 1.95) for the severe hepatic impaired groups compared to the normal hepatic function group. For the unbound entrectinib and M5, the AUC_{last (fu)} geometric mean ratio (90% CI) were 1.91 (1.21, 3.02) for the mild, 1.57 (1.06, 2.31) for the moderate, and 2.34 (1.57, 3.48) for the severe hepatic impaired groups compared to the normal hepatic function group. Although the effect of hepatic impairment on unbound PK parameters generally

followed a similar direction as total PK parameters, due to the high non-specific binding in buffer and high variability, results should be interpreted with caution. In addition to the modest increases in entrectinib exposure observed, the variability in systemic exposure was high and observed exposures overlapped across all the study groups (see also sections 4.2 *Dose and method of administration* and 5.2 *Pharmacokinetic properties*).

Use in renal impairment

Rozlytrek has not been studied in patients with severe (CLcr < 30 mL/min) renal impairment (see sections 4.2 *Dose and method of administration* and 5.2 *Pharmacokinetic properties*).

Use in the elderly

Of the 355 patients who received Rozlytrek across clinical trials, 25% were 65 years or older, and 5% were 75 years of age or older. Clinical studies of Rozlytrek did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients.

Effects on laboratory tests

See section 4.8 Adverse effects (undesirable effects) – Laboratory abnormalities.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Effects of entrectinib on other drugs

CYP substrates

Co-administration of a single 600 mg Rozlytrek dose with oral midazolam (a sensitive CYP3A substrate) in patients increased the midazolam AUC by 50% but reduced midazolam C_{max} by 21%. See section 4.2 *Dose and method of administration – dose modifications for specific medicine interactions*.

Transporter substrates

Co-administration of a single 600 mg Rozlytrek dose with oral digoxin (a sensitive P-glycoprotein (P-gp) substrate) in patients increased digoxin C_{max} by 28% and AUC by 18%.

In vitro data indicates:

- Entrectinib is not a substrate of P-gp or BCRP, but M5 is a substrate of both.
- Entrectinib and M5 are not substrates of OATP1B1 or OATP1B3.

Oral contraceptives

Physiologically-based pharmacokinetic simulation does not predict a significant effect of entrectinib on the pharmacokinetics of ethinyl oestradiol.

Effects of other drugs on entrectinib

CYP3A inducers

Co-administration of a single oral 600 mg dose of entrectinib with rifampicin (a strong CYP3A inducer) reduced entrectinib AUC_{inf} by 77% and C_{max} by 56%. Co-administration of a moderate CYP3A inducer with Rozlytrek is predicted to reduce AUC_{0-tau} by 56% and C_{max} by 43%. See section 4.2 *Dose and method of administration – Dose modifications for specific medicine interactions*.

CYP3A inhibitors

Co-administration of a single oral 100 mg dose of entrectinib with itraconazole (a strong CYP3A4 inhibitor) increased entrectinib AUC_{inf} by 504% (6-fold) and C_{max} by 73%. Co-administration of a moderate CYP3A inhibitor with Rozlytrek is predicted to increase entrectinib AUC_{0-Tau} by 3-fold and C_{max} by 2.9-fold. See section 4.2 *Dose and method of administration – Dose modifications for specific medicine interactions*.

Medicinal products that increase gastric pH

Co-administration of a single oral 600 mg dose of entrectinib with lansoprazole (a proton pump inhibitor [PPI]) decreased entrectinib AUC_{inf} by 25% and C_{max} by 23%.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

Dedicated toxicological fertility studies of entrectinib have not been performed. In general toxicology studies, with the exception of dose-dependent decreases in prostate weight in male dogs, no effects of entrectinib on reproductive organs were observed in rats or dogs at doses resulting in exposures up to approximately 3.2 times the human exposure (AUC) at the recommended human dose (600 mg).

Use in pregnancy - Category D

There are no available data on the use of Rozlytrek in pregnant women, but based on its mechanism of action, findings in animal studies (see below), and published clinical case reports of inherited NTRK pathway deficiencies (see below), Rozlytrek can cause embryo-fetal harm when administered to a pregnant woman. Advise all patients, including pregnant women, of the potential harm to a fetus.

<u>Human data</u>

Published reports of individuals with congenital mutations in TRK pathway proteins suggest that decreases in TRK-mediated signalling are correlated with obesity, developmental delays, cognitive impairment, insensitivity to pain, and anhidrosis.

Animal data

Administration of entrectinib to pregnant rats during the period of organogenesis at a dose of 200 mg/kg (resulting in exposures up to 2.7 times the human exposure (AUC) at the 600 mg dose) resulted in maternal toxicity (decreased body weight gain and food consumption) and resulted in fetal malformations including body closure defects (omphalocele and gastroschisis) and malformations of the vertebrae, ribs and limbs (micromelia and adactyly), but did not result in embryolethality. Lower fetal weights and reduced skeletal ossification occurred at doses \geq 12.5 and 50 mg/kg, respectively (resulting in exposures equivalent to 0.2 and 0.9 times the human exposure (AUC) at the 600 mg dose, respectively).

Contraception in male and female patients

Rozlytrek can cause embryo-fetal harm when administered to a pregnant woman. Advise all patients of the potential harm to a fetus. Test for pregnancy in females of reproductive potential prior to initiating Rozlytrek. Advise female patients of reproductive potential to use highly

effective contraceptive methods during treatment with Rozlytrek and for at least 5 weeks following the last dose.

Advise male patients with female partners of reproductive potential to use highly effective contraceptive methods during treatment with Rozlytrek and for 3 months following the last dose.

Use in lactation

There are no data on the presence of entrectinib or its metabolites in human milk or their effects on either the breastfed child or on milk production. Because of the potential for harm to the breastfed child, advise a lactating woman to discontinue breastfeeding during treatment with Rozlytrek and for 7 days after the final dose.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Rozlytrek may influence the ability to drive and use machines. Advise patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions (see sections 4.4 *Special warnings and precautions for use* and 4.8 *Adverse effects (undesirable effects)*).

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Summary of the safety profile

The safety profile of Rozlytrek was characterised in a group of 355 patients, including 172 (48%) patients exposed for 6 months or longer and 84 (24%) patients exposed for 1 year or longer. Rozlytrek was studied in one dose-finding trial in adults [ALKA (n = 57)], one dose-finding and activity-estimating trial in adults [STARTRK-1 (n = 76)], one dose-finding and activity-estimating trial in paediatric and adult patients [STARTRK-NG (n = 16)], and one single arm, activity-estimating trial in adults [STARTRK-2 (n = 206)].

The population characteristics were: median age 55 years (range: 4 to 86 years); 5% (n = 17) were less than 18 years of age; 55% were female; and 66% were White, 23% were Asian, and 5% were Black; 3% were Hispanic/Latino. The most common tumours (\geq 5%) were lung (56%), sarcoma (8%), and colon (5%). ROS1 gene fusions were present in 42% and NTRK gene fusions were present in 20%. Most adults (75%) received Rozlytrek 600 mg orally once daily. The doses ranged from 100 mg/m² to 1600 mg/m² once daily in adults and 250 mg/m² to 750 mg/m² once daily in paediatric patients. Rozlytrek is not indicated for paediatric patients less than 12 years of age (see section 4.4 *Special warnings and precautions for use – Paediatric use*).

Serious adverse reactions occurred in 39% of patients. The most frequent serious adverse reactions ($\geq 2\%$) were pneumonia (3.9%), dyspnoea (3.7%), pleural effusion (3.4%), sepsis (2.5%), pulmonary embolism (2.3%), respiratory failure (2%), and pyrexia (2%).

Grade 3 or 4 adverse reactions occurred in 60% of patients; the most common ($\geq 2\%$) were lung infection (5%), increased weight (7%), dyspnoea (6%), fatigue/asthenia (5%), cognitive disorders (4.5%), syncope (2.5%), pulmonary embolism (3.4%), hypoxia (3.4%), pleural effusion (3.1%), hypotension (2.8%), diarrhoea (2%), and urinary tract infection (2.5%).

Fatal events included dyspnoea (0.6%), pneumonia (0.6%), sepsis (0.6%), completed suicide (0.3%), large intestine perforation (0.3%) and tumour lysis syndrome (0.3%). One patient

developed Grade 4 myocarditis after one dose of Rozlytrek which resolved after discontinuation of Rozlytrek and administration of high-dose corticosteroids.

Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received Rozlytrek. The most frequent adverse reactions (< 1% each) that resulted in permanent discontinuation were pneumonia, cardio-respiratory arrest, dyspnoea, and fatigue.

Dose interruptions due to adverse reactions occurred in 46% of patients. The most frequent adverse reactions ($\geq 2\%$) that resulted in interruption were increased blood creatinine (4%), fatigue (3.7%), anaemia (3.1%), diarrhoea (2.8%), pyrexia (2.8%), dizziness (2.5%), dyspnoea (2.3%), nausea (2.3%), pneumonia (2.3%), cognitive disorder (2%) and neutropenia (2%).

Dose reductions due to adverse reactions occurred in 29% of patients who received Rozlytrek. The most frequent adverse reactions resulting in dose reductions ($\geq 1\%$) were dizziness (3.9%), increased blood creatinine (3.1%), fatigue (2.3%), anaemia (1.7%), and increased weight (1.4%).

The most common adverse reactions ($\geq 20\%$) were fatigue, constipation, dysgeusia, oedema, dizziness, diarrhoea, nausea, dysaesthesia, dyspnoea, myalgia, cognitive impairment, increased weight, cough, vomiting, pyrexia, arthralgia and vision disorders.

Tabulated summary of adverse drug reactions from clinical trials

Table 4 summarises the most common adverse drug reactions (ADRs) occurring in adult and paediatric patients treated with Rozlytrek.

Table 4. Adverse reactions that occurred in at least 10% of patients receiving Rozlytrekin clinical trials (ALKA, STARTRK-1, STARTRK-2 and STARTRK-NG)

Adverse Reactions	ROZLYTREK N = 355		
	All Grades (%)	Grade≥3* (%)	
General disorders and a	administration site c	onditions	
Fatigue ¹	48	5	
Edema ²	40	1.1	
Pyrexia	21	0.8	
Gastrointestinal			
Constipation	46	0.6	
Diarrhoea	35	2.0	
Nausea	34	0.3	
Vomiting	24	0.8	
Abdominal pain ³	16	0.6	
Nervous system disorde	rs		
Dysgeusia	44	0.3	
Dizziness ⁴	38	0.8	
Dysesthesia ⁵	34	0.3	
Cognitive	27	4.5	
impairment ⁶			
Peripheral sensory	18	1.1	
neuropathy ⁷			
Headache	18	0.3	
Ataxia ⁸	17	0.8	

	ROZLYTREK		
Adverse Reactions	All Grades (%)	N = 355 Grade ≥ 3* (%)	
Sleep ⁹	14	0.6	
Sleep ⁹ Mood disorders ¹⁰		0.6	
	10		
Respiratory, thoracic an			
Dysopnea	30	6*	
Cough	24	0.3	
Musculoskeletal and con	nnective tissue disor	ders	
Myalgia ¹¹	28	1.1	
Arthralgia	21	0.6	
Muscular weakness	12	0.8	
Back pain	12	1	
Pain in extremity	11	0.3	
Metabolism and nutritie	on disorders		
Increased weight	25	7	
Decreased appetite	13	0.3	
Dehydration	10	1.1	
Eye disorders			
Vision disorders ¹²	21	0.8	
Infections and infestation	ons		
Urinary tract	13	2.3	
infection			
Lung infection ¹³	10	6*	
Vascular disorders			
Hypotension ¹⁴	18	2.8	
Skin and subcutaneous	tissue disorders		
Rash ¹⁵	11	0.8	

* Grades 3-5, inclusive of fatal adverse reactions, including 2 events of pneumonia and 2 events of dysopnea.

¹Includes fatigue, asthenia

² Includes face edema, fluid retention, generalized edema, localized edema,

edema, edema peripheral, peripheral swelling

³ Includes abdominal pain upper, abdominal pain, lower abdominal discomfort, abdominal tenderness

⁴ Includes dizziness, vertigo, dizziness postural

⁵ Includes paresthesia, hyperesthesia, hypoesthesia, dysesthesia, oral hypoesthesia, palmar-plantar erythrodysesthesia, oral paresthesia, genital hypoesthesia

⁶ Includes amnesia, aphasia, cognitive disorder, confusional state, delirium, disturbance in attention, hallucinations, visual hallucination, memory impairment, mental disorder, mental status changes

⁷ Includes neuralgia, neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy

⁸ Includes ataxia, balance disorder, gait disturbances

⁹ Includes hypersomnia, insomnia, sleep disorder, somnolence

¹⁰ Includes anxiety, affect lability, affective disorder, agitation, depressed mood, euphoric mood, mood altered, mood swings, irritability, depression, persistent depressive disorder, psychomotor retardation

¹¹ Includes musculoskeletal pain, musculoskeletal chest pain, myalgia, neck pain ¹² Includes blindness, cataract, cortical cataract, corneal erosion, diplopia, eye disorder, photophobia, photopsia, retinal hemorrhage, vision blurred, visual

impairment, vitreous adhesions, vitreous detachment, vitreous floaters ¹³ Includes lower respiratory tract infection, lung infection, pneumonia,

respiratory tract infection

¹⁴ Includes hypotension, orthostatic hypotension

Adverse Reactions	ROZLYTREK N = 355	
	All Grades (%)	Grade≥3* (%)

¹⁵ Includes rash, rash maculopapular, rash pruritic, rash erythematous, rash papular

Clinically relevant adverse reactions that occurred in $\leq 10\%$ of patients include dysphagia (10%), fall (8%), pleural effusion (8%), fractures (6%), hypoxia (4.2%), pulmonary embolism (3.9%), syncope (3.9%), congestive heart failure (3.4%), and QT prolongation (3.1%).

Description of selected adverse drug reactions

Congestive heart failure (CHF)

Among the 355 patients who received Rozlytrek across clinical trials, congestive heart failure (CHF) occurred in 3.4% of patients, including Grade 3 (2.3%). In clinical trials, cardiac monitoring was conducted using electrocardiograms (ECGs) and echocardiograms or multigated acquisition (MUGA) scans at baseline and at specified time points during treatment with Rozlytrek. Study eligibility criteria excluded patients with symptomatic CHF, myocardial infarction, unstable angina, or coronary artery bypass graft within 3 months of study entry. Among the 12 patients with CHF, the median time to onset was 2 months (range: 11 days to 12 months). Rozlytrek was interrupted in 6 of these patients (50%) and discontinued in 2 of these patients (17%). CHF resolved in 6 patients (50%) following interruption or discontinuation of Rozlytrek and institution of appropriate medical management. In addition, myocarditis in the absence of CHF was documented in 0.3% of patients. See also section 4.4 Special warnings and precautions for use.

Central nervous system effects

Among the 355 patients who received Rozlytrek across clinical trials, 96 (27%) experienced cognitive impairment; symptoms occurred within 3 months of starting Rozlytrek in 74 (77%). Cognitive impairment included cognitive disorders (8%), confusional state (7%), disturbance in attention (4.8%), memory impairment (3.7%), amnesia (2.5%), aphasia (2.3%), mental status changes (2%), hallucinations (1.1%), and delirium (0.8%). Grade 3 cognitive adverse reactions occurred in 4.5% of patients. Among the 96 patients with cognitive impairment, 13% required a dose reduction, 18% required dose interruption and 1% discontinued Rozlytrek due to cognitive adverse reactions.

Among the 355 patients who received Rozlytrek across clinical trials, 36 (10%) experienced mood disorders. The median time to onset of mood disorders was 1 month (range: 1 day to 9 months). Mood disorders occurring in \geq 1% of patients included anxiety (4.8%), depression (2.8%) and agitation (2%). Grade 3 mood disorders occurred in 0.6% of patients. One completed suicide was reported 11 days after treatment had ended. Among the 36 patients who experienced mood disorders, 6% required a dose reduction, 6% required dose interruption and no patients discontinued Rozlytrek due to mood disorders.

Dizziness occurred in 136 (38%) of the 355 patients. Among the 136 patients who experienced dizziness, Grade 3 dizziness occurred in 2.2% of patients. Ten percent of patients required a dose reduction, 7% required dose interruption and 0.7% discontinued Rozlytrek due to dizziness.

Among the 355 patients who received Rozlytrek across clinical trials, 51 (14%) experienced sleep disturbances. Sleep disturbances included insomnia (7%), somnolence (7%), hypersomnia (1.1%), and sleep disorder (0.3%). Grade 3 sleep disturbances occurred in 0.6% of patients. Among the 51 patients who experienced sleep disturbances, 6% required a dose reduction and no patients discontinued Rozlytrek due to sleep disturbances.

The incidence of CNS adverse reactions was similar in patients with and without CNS metastases; however, the incidence of dizziness (38% vs 31%), headache (21% vs 13%), paraesthesia (20% vs 6%), balance disorder (13% vs 4%), and confusional state (11% vs 2%) appeared to be increased in patients with CNS metastases who had received prior CNS irradiation (N = 90) compared to those who did not (N = 48). Patients who had brain metastases at baseline had a higher frequency of these events (39%) compared to those without brain metastases (25%).

See also section 4.4 Special warnings and precautions for use.

Skeletal fractures

In an expanded safety population that included 338 adult patients and 30 paediatric patients who received Rozlytrek across clinical trials, 5% of adult patients and 23% of paediatric patients experienced fractures (see section 4.8 *Adverse effects (undesirable effects)*). In adult patients, some fractures occurred in the setting of a fall or other trauma to the affected area, while in paediatric patients all fractures occurred in patients with minimal or no trauma. In general, there was inadequate assessment for tumour involvement at the site of fracture; however, radiologic abnormalities possibly indicative of tumour involvement were reported in some patients. In both adult and paediatric patients, most fractures were hip or other lower extremity fractures (e.g., femoral or tibial shaft). In a limited number of patients, bilateral femoral neck fractures occurred. The median time to fracture was 3.8 months (range 0.3 to 18.5 months) in adults and 4.0 months (range: 1.8 months to 7.4 months) in paediatric patients. No patients discontinued Rozlytrek due to fractures. See also section *4.4 Special warnings and precautions for use*.

Hepatotoxicity

Among the 355 patients who received Rozlytrek, increased AST of any grade occurred in 42% of patients and increased ALT of any grade occurred in 36%. Grade 3 – 4 increased AST or ALT occurred in 2.5% and 2.8% of patients, respectively; the incidence may be underestimated as 4.5% of patients had no post-treatment liver function tests (see Table 5). The median time to onset of increased AST was 2 weeks (range: 1 day to 29.5 months). The median time to onset of increased ALT was 2 weeks (range: 1 day to 9.2 months). Increased AST or ALT leading to dose interruptions or reductions occurred in 0.8% and 0.8% of patients, respectively. Rozlytrek was discontinued due to increased AST or ALT in 0.8% patients. See also section 4.4 Special warnings and precautions for use.

Hyperuricaemia

Among 355 patients who received Rozlytrek across clinical trials, 32 patients (9%) experienced hyperuricaemia reported as adverse reactions with symptoms, as well as elevated uric acid levels. Grade 4 hyperuricaemia occurred in 1.7% of patients, including one patient who died due to tumour lysis syndrome. Among the 32 patients with hyperuricaemic adverse reactions, 34% required urate-lowering medication to reduce uric acid levels, 6% required dose reduction and 6% required dose interruption. Hyperuricaemia resolved in 73% of patients following initiation of urate-lowering medication without interruption or dose reduction of Rozlytrek. No

patients discontinued Rozlytrek due to hyperuricaemia. See also section 4.4 Special warnings and precautions for use.

QT interval prolongation

Among the 355 patients who received Rozlytrek across the clinical trials, 3.1% of patients with at least one post-baseline ECG assessment experienced QTcF interval prolongation of >60 ms after starting Rozlytrek and 0.6% had a QTcF interval >500 ms (see sections 4.4 Special warnings and precautions for use and 5.1 Pharmacodynamic properties).

Vision disorders

Among the 355 patients who received Rozlytrek across clinical trials, vision changes occurred in 21% of patients, including Grade 1 (82%), Grade 2 (14%) and Grade 3 (0.8%). Vision disorders occurring in \geq 1% included blurred vision (8.7%), photophobia (5.1%), diplopia (3.1%), visual impairment (2%), photopsia (1.3%), cataract (1.1%), and vitreous floaters (1.1%). See also section 4.4 Special warnings and precautions for use.

Weight gain

Increased weight was reported by around a quarter of adult patients, 7% at grade 3 severity (an increase of more than 20% from baseline). Fluid retention or oedema was co-reported for a number of cases and may have contributed to weight gain. Among 30 paediatric patients treated with entrectinib for various NTRK-positive cancers, six (20%) reported grade 3 weight increase.

Laboratory abnormalities

Table 5 summarises the laboratory abnormalities that most commonly worsened from baseline in adult and paediatric patients treated with Rozlytrek.

Laboratory Abnormality	ROZLYTREK NCI CTCAE Grade		
<i>. .</i>	All Grades (%) ¹	Grade 3 or 4 (%) ¹	
Hematology			
Anaemia	67	9	
Lymphopenia	40	12	
Neutropenia	28	7	
Chemistry			
Increased creatinine ²	73	2.1	
Hyperuricemia	52	10	
Increased AST	44	2.7	
Increased ALT	38	2.9	
Hypernatremia	35	0.9	
Hypocalcemia	34	1.8	
Hypophosphatemia	30	7	
Increased lipase	28	10	
Hypoalbuminemia	28	2.9	
Increased amylase	26	5.4	
Hyperkalemia	25	1.5	
Increased alkaline phosphatase	25	0.9	
Hyperglycemia ³	NE ³	3.8	

Table 5: Laboratory abnormalities (≥ 20%) worsening from baseline in patients receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG

AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase

¹Denominator for each laboratory parameter is based on the number of patients with a baseline and posttreatment laboratory value available which ranged from 111 to 346 patients.

²Based on NCI CTCAE v5.0

 3 NE = Not evaluable. Grade 1 and 2 could not be determined per NCI CTCAE v5.0, as fasting glucose values were not collected.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <u>www.tga.gov.au/reporting-problems</u>.

4.9 **OVERDOSE**

There is no experience with overdose in clinical trials with Rozlytrek. Patients who experience overdose should be closely supervised and supportive care instituted. There are no known antidotes for Rozlytrek.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5. PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Antineoplastic agent, tyrosine kinase inhibitor, ATC code: L01EX14.

Mechanism of Action

Entrectinib is an inhibitor of the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB and TRKC (encoded by the neurotrophic tyrosine receptor kinase [*NTRK*] genes *NTRK1*, *NTRK2* and *NTRK3*, respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1; encoded by the gene *ROS1*), and anaplastic lymphoma kinase (ALK; encoded by the gene *ALK*) with IC₅₀ values of 0.1 to 2 nM. Entrectinib also inhibits JAK2 and TNK2 with IC50 values > 5 nM. The major active metabolite of entrectinib, M5, showed similar *in vitro* activity against TRK, ROS1 and ALK.

Fusion proteins that include TRK, ROS1 or ALK kinase domains can drive tumourigenic potential through hyperactivation of downstream signalling pathways leading to unconstrained cell proliferation. Entrectinib inhibits the TRK kinases, ROS1 and ALK, leading to inhibition of downstream signalling pathways, cell proliferation and induction of tumour cell apoptosis. Entrectinib demonstrated *in vitro* and *in vivo* inhibition of cancer cell lines derived from multiple tumour types harbouring NTRK, ROS1 and ALK fusion genes.

Entrectinib demonstrated steady-state brain-to-plasma concentration ratios of 0.4 - 2.2 in multiple animal species (mice, rats and dogs) and demonstrated *in vivo* anti-tumour activity in mice with intracranial implantation of TRKA- and ALK-driven tumour cell lines.

Cardiac electrophysiology

Across clinical trials, 355 patients who received Rozlytrek (at doses ranging from 100 mg to 2600 mg daily under fasting or fed conditions; 75% received 600 mg orally once daily) had at least one post-baseline ECG assessment. Amongst this group, 3.1% experienced QTcF prolongation of more than 60 ms past their baseline after starting Rozlytrek, and 0.6% had a

post-baseline QTc interval longer than 500 ms (see section 4.4 *Warnings and special precautions for use.*)

Clinical trials

ROS1-positive NSCLC

The efficacy of Rozlytrek was evaluated in a pooled subgroup of patients with ROS1-positive metastatic NSCLC who received Rozlytrek at various doses and schedules (90% received Rozlytrek 600 mg orally once daily) and were enrolled in one of three multicentre, single-arm, open-label clinical trials: ALKA, STARTRK-1 and STARTRK-2. To be included in this pooled subgroup, patients were required to have histologically confirmed, recurrent or metastatic, ROS1-positive NSCLC, ECOG performance status ≤ 2 , measurable disease per RECIST v1.1, ≥ 18 months of follow-up from first post-treatment tumour assessment, and no prior therapy with a ROS1 inhibitor. Identification of ROS1 gene fusion in tumour specimens was prospectively determined in local laboratories using either a fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), or polymerase chain reaction (PCR) laboratory-developed tests. All patients were assessed for CNS lesions at baseline. The primary efficacy outcome measures were overall response rate (ORR) and duration of response (DOR) according to RECIST v1.1 as assessed by blinded independent central review (BICR). Intracranial response according to RECIST v1.1 was assessed by BICR. Tumour assessments with imaging were performed every 8 weeks.

Efficacy was assessed in 92 patients with ROS1-positive NSCLC. The median age was 53 years (range: 27 to 86); female (65%); White (48%), Asian (45%), Black (5%); and Hispanic or Latino (2.4%); never smoked (59%); and ECOG performance status 0 or 1 (88%). Ninetynine percent of patients had metastatic disease, including 42% with CNS metastases; 96% had adenocarcinoma; 65% received prior platinum-based chemotherapy for metastatic or recurrent disease or had progressed in less than 6 months following platinum-based adjuvant or neoadjuvant therapy. ROS1 positivity was determined by NGS in 79%, FISH in 16%, and PCR in 4%. Twenty-five percent had central laboratory confirmation of ROS1 positivity using an analytically validated RNA-based NGS test.

Efficacy results from patients with ROS1-positive NSCLC are summarised in Table 6.

Efficacy Parameters	Rozlytrek
Objective response rate (ORR)	n = 92
ORR (95% CI)	74% (64, 83)
CR, n (%)	14 (15%)
PR, n (%)	54 (59%)
Duration of response (DOR)*	n = 68
Range (months)	2.4, 55.2+
% with duration ≥ 9 months	75%
% with duration ≥ 12 months	57%
% with duration ≥ 18 months	38%

Table 6. Efficacy results for patients with ROS1-positive NSCLC per BICR assessment.

CR = complete response; PR = partial response;

Confidence Intervals (CI) calculated using the Clopper-Pearson method.

*Observed DOR

+ denotes ongoing response

Of the 92 patients with ROS1-positive NSCLC in the efficacy evaluable analysis set, 10 had measurable CNS metastases at baseline as assessed by BICR and had not received radiation

therapy to the brain within 2 months prior to study entry. Responses in intracranial lesions were observed in 7 of these 10 patients.

NTRK fusion-positive solid tumours

Efficacy in adult patients

The efficacy of Rozlytrek was evaluated in a pooled subgroup of adult patients with unresectable or metastatic solid tumours with a NTRK gene fusion enrolled in one of three multicentre, single-arm, open-label clinical trials: ALKA, STARTRK-1 and STARTRK-2. To be included in this pooled subgroup, patients were required to have progressed following systemic therapy for their disease, if available, or would have required surgery causing significant morbidity for locally advanced disease; measurable disease per RECIST v1.1; at least 2 years of follow-up from first post-treatment tumour assessment of Rozlytrek; and no prior therapy with a TRK inhibitor. Patients received Rozlytrek at various doses and schedules (94% received Rozlytrek 600 mg orally once daily) until unacceptable toxicity or disease progression. Identification of positive NTRK gene fusion status was prospectively determined in local laboratories or a central laboratory using various nucleic acid-based tests. The major efficacy outcome measures were ORR and DOR, as determined by a BICR according to RECIST v1.1. Intracranial response according to RECIST v1.1 as evaluated by BICR. Tumour assessments with imaging were performed every 8 weeks.

Efficacy was assessed in the first 54 adult patients with solid tumours with an NTRK gene fusion enrolled into these trials. The median age was 58 years (range: 21 to 83); female (59%); White (80%), Asian (13%) and Hispanic or Latino (7%); and ECOG performance status 0 (43%) or 1 (46%). Ninety-six percent of patients had metastatic disease, including 22% with CNS metastases, and 4% had locally advanced, unresectable disease. All patients had received prior treatment for their cancer including surgery (n=43), radiotherapy (n=36), or systemic therapy (n=48). Forty patients (74%) received prior systemic therapy for metastatic disease with a median of 1 prior systemic regimen and 17% (n=9) received 3 or more prior systemic regimens. The most common cancers were sarcoma (24%), lung cancer (19%), salivary gland tumours (13%), breast cancer (11%), thyroid cancer (9%), and colorectal cancer (7%). A total of 52 (96%) patients had an NTRK gene fusion detected by NGS and 2 (4%) had an NTRK gene fusion detected by other nucleic acid-based tests. Eighty-three percent of patients had central laboratory confirmation of NTRK gene fusion using an analytically validated RNA-based NGS test.

Efficacy results from patients with NTRK-positive solid tumours are summarised in Table 7.

Efficacy Parameter	Rozlytrek	
Objective response rate (ORR)	n=54	
ORR (95% CI)	59% (45, 72)	
CR, n (%)	7 (13%)	
PR, n (%)	25 (46%)	
Duration of response (DOR)*	n=32	
Range, (months)	2.8, 47.8+	
% with duration ≥ 6 months	72%	
% with duration \geq 9 months	66%	
% with duration ≥ 12 months	56%	

Table 7. Efficacy results for patients with solid tumours harbouring an NTRK gene fusion

CR = complete response; PR = partial response.

Confidence Intervals (CI) calculated using the Clopper-Pearson method.

* Observed DOR

+ denotes ongoing response

	Dationta	ORR		DOR
Tumor Type	Patients N = 54	%	95% CI	Range (months)
Sarcoma	13	46%	19%, 75%	2.8, 33.6+
Non-small cell lung	10	60%	26%, 88%	3.7, 47.8+
cancer				
Salivary (MASC)	7	86%	42%, 100%	2.8, 38.5+
Breast cancer	6	83%	36%, 100%	4.2, 42.3+
Thyroid cancer	5	60%	NA	7.9, 31.5+
Colorectal cancer	4	25%	NA	15.1
Neuroendocrine cancers	3	CR	NA	32.9+
Pancreatic cancer	3	PR, PR	NA	7.1, 12.9
Gynecological cancers	2	PR	NA	38.2
Cholangiocarcinoma	1	PR	NA	9.3

Table 8: Efficacy against NTRK fusion-positive tumours, by tumour histology

+ denotes ongoing response

MASC: mammary analogue secretory carcinoma; NA = not applicable; PR = partial response.

Table 9. Efficacy against NTRK fusion-positive tumours, by fusion gene partner

NTRK Partner	Patients N = 54	ORR		DOR
		%	95% CI	Range (months)
ETV6 – NTRK3	25	72%	51%, 88%	2.8, 47.8+
TPM3 – NTRK1	4	50%	7%, 93%	2.8, 15.1
TPR – NTRK1	4	100%	40%, 100%	5.6, 33.6+
LMNA – NTRK1	2	PR, PD	NA	4.2
SQSTM1 – NTRK1	2	PR, PD	NA	18.8 +
PEAR1 – NTRK1	2	SD, NE	NA	NA
EML4 – NTRK3	2	PR, NE	NA	13.2
CD74 – NTRK1	1	PR	NA	10.4
PLEKHA6 – NTRK1	1	PR	NA	9.3
CDC42BPA - NTRK1	1	PR	NA	29.4
EPS15L1 - NTRK1	1	PR	NA	3.7
RBPMS – NTRK3	1	PR	NA	4.6
ERC1 – NTRK1	1	SD	NA	NA
PDIA3 – NTRK1	1	SD	NA	NA
TRIM33 – NTRK1	1	SD	NA	NA
AKAP13 – NTRK3	1	SD	NA	NA
KIF7 – NTRK3	1	SD	NA	NA
FAM19A2 – NTRK3	1	PD	NA	NA
CGN – NTRK1	1	NE	NA	NA
SQSTM1 – NTRK2	1	NE	NA	NA

+ denotes ongoing response

PR = partial response; PD = progressive disease; SD = stable disease; NA = not applicable; NE = not evaluable.

Among the subset of patients who received prior systemic therapy for metastatic disease, the ORR was 53%, similar to that seen in the overall population.

Among the 54 adult patients, 4 had measurable CNS metastases at baseline as assessed by BICR and had not received radiation therapy to the brain within 2 months of study entry. Responses in intracranial lesions were observed in 3 of these 4 patients.

5.2 PHARMACOKINETIC PROPERTIES

The pharmacokinetics of entrectinib and its pharmacologically active major circulating metabolite (M5) were characterised in adult patients with *ROS1*-positive NSCLC, *NTRK* gene fusion-positive solid tumours and, and healthy subjects. The pharmacokinetics of entrectinib and M5 are linear and are not dose-dependent or time-dependent. Steady state is achieved within one week for entrectinib and two weeks for M5 following daily administration of Rozlytrek. The pharmacokinetic parameters for entrectinib and M5 are described in Table 10.

Parameter	Entrectinib Mean* (% CV)	M5 Mean* (% CV)
AUC _{D1} (nM*h)	31800 (48%)	10200 (82%)
AUC _{ss} (nM*h)	48000 (77%)	24000 (97%)
C _{maxD1} (nM)	2250 (58%)	622 (79%)
C _{maxss} (nM)	3130 (80%)	1250 (90%)
R _{acc(AUC)}	1.55 (49%)	2.84 (93%)

Table 10. Pharmacokinetic parameters for entrectinib and metabolite M5

* Geometric mean

Absorption

The maximum entrectinib plasma concentration was reached 4 to 6 hours after oral administration of a 600 mg dose.

Effect of food

A high-fat (approximately 50% of total caloric content), high-calorie (approximately 800 to 1000 calories) meal did not have a significant effect on entrectinib exposure.

Distribution

Entrectinib and its major active metabolite M5 are both >99% bound to human plasma proteins *in vitro*.

The estimated volume of distribution (V/F) of 551 L and 81.1 L for entrectinib and M5, respectively.

Metabolism

Entrectinib is metabolised predominantly by CYP3A4 (~76%). Minor contributions from several other CYPs and UGT1A4 were estimated at < 25% in total. The active metabolite M5 (formed by CYP3A4) is the only major active circulating metabolite identified. M5 has similar pharmacological potency to entrectinib in vitro and circulating M5 exposures at steady-state in patients were 40% of the corresponding entrectinib exposure.

Excretion

Following administration of a single oral dose of $[^{14}C]$ -labelled entrectinib, 83% of radioactivity was excreted in faeces (36% of the dose as unchanged entrectinib and 22% as M5) with minimal excretion in urine (3%).

The estimated apparent clearance (CL/F) was 19.6 L/h and 52.4 L/h for entrectinib and M5, respectively. The elimination half-lives of entrectinib and M5 were estimated to be 20 and 40 hours, respectively.

Pharmacokinetics in special populations

No clinically significant differences in the pharmacokinetics of entrectinib were observed based on age (12 years to 86 years), sex, race (White, Asian and Black), body weight (32 to 130 kg), mild to moderate renal impairment (CLcr 30 to <90 mL/min) and hepatic impairment (see section 4.4 Special warnings and precautions for use).

Paediatric population (12 years and older)

In paediatric patients 12 years and older, the predicted systemic exposures for body surface area-based doses of 600 mg (BSA >1.50 m²), 500 mg (BSA of 1.11 to 1.50 m²) and 400 mg (BSA of 0.91 to 1.10 m²) are comparable to the exposure in adults at the 600 mg dose.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Entrectinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay; however, an in vitro assay in cultured human peripheral blood lymphocytes did demonstrate a potential for abnormal chromosome segregation (aneugenicity). Entrectinib was not clastogenic or aneugenic in the in vivo micronucleus assay in rats and did not induce DNA damage in a comet assay in rats.

Carcinogenicity

No carcinogenicity studies have been performed to establish the carcinogenic potential of entrectinib.

Juvenile animal toxicity

In a 13-week juvenile rat toxicology study, animals were dosed daily from post-natal day 7 to day 97 (approximately equivalent to neonate to 16 years of age in humans). Entrectinib resulted in:

- decreased body weight gain and delayed sexual maturation at doses \geq 4 mg/kg/day (approximately 0.06 times the human exposure (AUC) at the 600 mg dose),
- deficits in neurobehavioral assessments including functional observational battery and learning and memory (at doses ≥8 mg/kg/day, approximately 0.14 times the human exposure at the 600 mg dose), and
- decreased femur length at doses $\geq 16 \text{ mg/kg/day}$ (approximately 0.18 times the human exposure at the 600 mg dose).

See also section 4.4 Special warnings and precautions for use – Paediatric use.

6. PHARMACEUTICAL PARTICULARS6.1 LIST OF EXCIPIENTS

Capsule content

Lactose Microcrystalline cellulose Tartaric acid Hypromellose

Crospovidone Magnesium stearate Colloidal anhydrous silica

Capsule shell

Hypromellose Titanium dioxide Iron oxide yellow (100 mg capsule only) Sunset yellow FCF (200 mg capsule only)

Printing ink

Shellac Propylene glycol Strong ammonia solution Indigo carmine aluminium lake

6.2 INCOMPATIBILITIES

Not applicable.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C. Keep capsules in the original bottle. Keep the bottle tightly closed to protect from moisture.

This medicine should not be used after the expiry date (EXP) shown on the pack.

6.5 NATURE AND CONTENTS OF CONTAINER

Rozlytrek hard capsules are packaged in white high-density polyethylene bottles with desiccant and a child-resistant screw cap.

100 mg hard capsules are supplied in bottles of 30 capsules.

200 mg hard capsules are supplied in bottles of 90 capsules.


6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

The release of pharmaceuticals in the environment should be minimised. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided.

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSIOCHEMICAL PROPERTIES

Chemical structure



CAS number

1108743-60-7

7. MEDICINE SCHEDULE (POISONS STANDARD)

Schedule 4 – Prescription Only Medicine

8. SPONSOR

Roche Products Pty Limited ABN 70 000 132 865 Level 8, 30 – 34 Hickson Road Sydney NSW 2000 AUSTRALIA

Medical enquiries: 1800 233 950

9. DATE OF FIRST APPROVAL

15 May 2020

10. DATE OF REVISION

22 December 2023

Summary table of changes

Section Changed	Summary of new information	
4.2, 4.4, 5.2	Updated information for patients with hepatic impairment	